Dividend, Technical Update, Financial Result, Expansion of Facility, and Earnings and Conference Call Schedule - Research Reports on Dr. Pepper Snapple, Colgate, Dean Foods, Herbalife and PVH

NEW YORK, August 14, 2014 /PRNewswire/ --

Today, Analysts Review released its research reports regarding Dr. Pepper Snapple Group Inc. (NYSE: DPS), Colgate-Palmolive Company (NYSE: CL), Dean Foods Co. (NYSE: DF), Herbalife Ltd. (NYSE: HLF) and PVH Corp. (NYSE: PVH). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5731-100free.

--
Dr. Pepper Snapple Group Inc. Research Reports
On August 7, 2014, Dr. Pepper Snapple Group Inc. (Dr. Pepper Snapple) announced that its Board of Directors has declared a quarterly dividend of $0.41 per share on its common stock, payable on October 3, 2014 to unit holders of record as on September 15, 2014. The recently announced dividend of Dr. Pepper Snapple is unchanged from the dividend announced in the previous quarter. The full research reports on Dr. Pepper Snapple are available to download free of charge at:

http://www.analystsreview.com/Aug-14-2014/DPS/report.pdf

--
Colgate-Palmolive Company Research Reports
On August 11, 2014, Colgate-Palmolive Company's (Colgate) stock declined 0.18% to end the trading session at $ 65.06, underperforming the S&P 500 that moved up 0.28% over the same trading session. Shares in Colgate opened the session at $65.34 and oscillated in the range of $65.01 - $65.70. Over the past six months, the stock has gained 5.07%, which is largely in line with the S&P 500 that returned 6.47% over the same period of time. The full research reports on Colgate are available to download free of charge at:

http://www.analystsreview.com/Aug-14-2014/CL/report.pdf

--
Dean Foods Co. Research Reports
On August 11, 2014, Dean Foods Co. (Dean Foods) released its Q2 2014 and H1 2014 financial results. In Q2 2014, the Company's net loss attributable to Dean Foods narrowed to $0.6 million or $0.01 diluted loss per share, from a net loss of $56.9 million or $0.61 diluted loss per share in Q2 2013. The Company reported Q2 2014 net sales of $2.39 billion, up 7.5% YoY. Analysts polled by Thomson Reuters expected the Company to post Q2 2014 EPS of $0.06 (excluding special items) on revenues of $2.32 billion. The Company's H1 2014 net sales improved 4.8% YoY to $4.7 billion, while net loss attributable to Dean Foods stood at $9.6 million, compared to net income of $435.7 million in H1 2013. Gregg Tanner, CEO, Dean Foods, said, "The balance of the year appears rocky, with a continued unpredictable and volatile dairy commodity environment. That makes it difficult to provide guidance beyond the immediate quarter. Therefore for the time being, we are going to provide specific guidance only for the next quarter, where our visibility is better. In this case, we expect an adjusted diluted net loss of between $0.05 and $0.15 per share in the third quarter." The full research reports on Dean Foods are available to download free of charge at:

http://www.analystsreview.com/Aug-14-2014/DF/report.pdf

--
Herbalife Ltd. Research Reports
On July 31, 2014, Herbalife Ltd. (Herbalife) announced that it is planning to expand its manufacturing capabilities in China, in an effort to increase its capacity in line with anticipated growth in the strategically important Chinese market. The Company stated that the recent expansion will be an addition to its existing manufacturing facilities in Suzhou, and its botanical extraction plant in Changsha. Further, the Company has selected newly built facility in Jiangning High-tech Industry Park (JHIP), Nanjing as the location for its newest manufacturing facility, due to the unique environment it provides for companies operating in the life science industries, as well as the relative speed to operation in having only to renovate an existing facility. The Company plans an investment of $40 million for the first phase development of the facility, which is expected to be complete and operational by the end of 2015. In addition, this new facility will ultimately provide up to 65% of the Company's total product requirements in China. The full research reports on Herbalife are available to download free of charge at:

http://www.analystsreview.com/Aug-14-2014/HLF/report.pdf

--
PVH Corp. Research Reports
On August 11, 2014, PVH Corp. (PVH) announced that it is planning to release its Q2 2014 financial results on September 3, 2014, after the market close. Following the result release, the Company will hold a conference call on September 4, 2014 at 9:00 a.m. ET to discuss its results. The Company informed that the conference call will be hosted by Emanuel Chirico, Chairman and CEO, and Michael Shaffer, Executive Vice President, Chief Operating & Financial Officer. The conference call will be broadcast live on PVH's official website. According to Bloomberg Businessweek's analysts, the Company is expected to post Q2 2014 EPS of $1.42 on revenues of $2.0 billion. The full research reports on PVH are available to download free of charge at:

http://www.analystsreview.com/Aug-14-2014/PVH/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.

===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

AnalystsReview.com

SOURCE Analysts Review